News & Updates
Filter by Specialty:
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
Antecedent use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) among older COVID-19 patients with hypertension results in fewer all-cause deaths, whether in-hospital or shortly after discharge, compared with no antecedent use of renin-angiotensin system inhibitors (RASIs), a study has shown.
BP-lowering drugs reduce death in older hypertensive COVID-19 patients
29 Mar 2022
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
In the treatment of patients with drug-resistant epilepsy associated with tuberous sclerosis complex, the antiseizure effect of cannabidiol occurs within 6–10 days, according to the results of a phase III trial. Adverse events also emerge during the first 2 weeks of the titration period, and majority of these are resolved during the 16-week treatment period.
Antiseizure effect of cannabidiol seen within 2 weeks of treatment
28 Mar 2022
IV steroids may do more harm than good in older-onset ulcerative colitis
In patients with older-onset ulcerative colitis (UC), treatment with intravenous (IV) steroids appears to be less effective and is associated with higher risks of surgery and adverse events relative to patients with younger-onset disease, a study has found.
IV steroids may do more harm than good in older-onset ulcerative colitis
26 Mar 2022
TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.
TYK2 inhibitor for psoriatic arthritis clears phase II trial
26 Mar 2022
TNFi use does not induce hypertension in ankylosing spondylitis
Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.
TNFi use does not induce hypertension in ankylosing spondylitis
25 Mar 2022
Apalutamide for castration-resistant prostate cancer yields real-world results
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
